ATG:biosynthetics GmbH

Based on our core competences in genomics, computational and synthetic biology ATG is the valuable partner for integrative biotech project plannings with a high impact on the development of new markets in a bio-based economy in terms of advanced bio-pharmaceutical, (veterinary-)medical, nutritional supply and bioindustry.
We have the potential, dynamic, attitude and aptitude for also realizing planned projects with and for our clients in all fields of the life sciences.
Our objective is either the functional integration of genes into higher order gene assemblies for creating gene clusters of biochemical pathways as well as for hetero-protein complex formation. The inverse direction of molecular biodesigns is the dissection of molecules to identify its minimal function. For this RNA, proteins and peptides (e.g. epitopes) are in ATG's focus. PepID is our brand for minimal target identification based on genomics and high density micro arrays.
ATG is all about artificial gene function. We provide our customers with synthetic genes, i.e. formal-operational in silico optimized gene sequences that promise maximum in vitro/ in vivo functional impact.
ATG is looking for customers and partnerships for projects creating products and services for pharmaceutical, medical, industrial and environmental use aiming at the development and marketing of high-potential synthetic biology applications.